Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma

Summary

This pilot phase I/II trial studies the side effects and best dose of plerixafor after radiation therapy and temozolomide and to see how well it works in treating patients with newly diagnosed high grade glioma. Plerixafor may stop the growth of tumor cells by blocking blood flow to the tumor. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high energy x rays to kill tumor cells. Giving plerixafor after radiation therapy and temozolomide may be an effective treatment for high grade glioma.

Conditions

• Adult Ependymoblastoma
• Adult Giant Cell Glioblastoma
• Adult Glioblastoma
• Adult Gliosarcoma
• Adult Medulloblastoma
• Adult Mixed Glioma
• Adult Oligodendroglial Tumors
• Adult Pineoblastoma
• Adult Supratentorial Primitive Neuroectodermal Tumor (PNET)

Interventions

RADIATION

radiation therapy

Undergo radiation therapy

DRUG

temozolomide

Given PO

DRUG

plerixafor

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

OTHER

pharmacological study

Correlative studies

Sponsors & Collaborators

• National Cancer Institute (NCI)

  collaborator NIH

• Lawrence Recht

  lead OTHER

Principal Investigators

• Lawrence Recht · Stanford University Hospitals and Clinics

Study Design

Allocation

NA

Purpose

TREATMENT

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Max Age

75 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2014-11-30

Primary Completion

2017-11-30

Completion

2018-09-30

Countries

• United States

Study Locations